Huadong Medicine: Daptomycin for injection of its subsidiary obtains US FDA approval

On November 28, Huadong Medicine issued an announcement stating that its wholly-owned subsidiary, Zhongmei Huadong, had recently received a notice from the FDA that the new drug application for daptomycin for injection declared by Zhongmei Huadong to the FDA had been approved

The "super antibiotic" daptomycin is a new generation of cycloaliphatic peptide antibiotics launched after vancomycin, and is regarded as a "milestone" progress in the field of antibiotics

Daptomycin was first discovered by Eli Lilly and developed by the pharmaceutical company CUBIST, and was approved for listing in China in 2009

In 2015, Huadong Medicine's daptomycin was approved to be listed in China and became the company's blockbuster product in the field of anti-infection

According to data from Meinenet, the domestic market of daptomycin in 2020 will be mainly occupied by three companies, of which Sino-US Huadong (a subsidiary of Huadong Pharmaceutical Holdings) accounted for about 45%, followed by Jiangsu Hengrui with 35%, and the original research drug Cubist.

Data source: Mi Nei.

In the international market, daptomycin has always been regarded as the antibiotic with the most growth potential

According to the announcement of Huadong Medicine, the approval of daptomycin for injection by the US FDA is an important result of the company's continuous enhancement of product research and development, improvement of product quality standards, and active promotion of the internationalization of preparations.